DE3582124D1 - Absorbierbares calcitoninarzneimittel. - Google Patents

Absorbierbares calcitoninarzneimittel.

Info

Publication number
DE3582124D1
DE3582124D1 DE8585308583T DE3582124T DE3582124D1 DE 3582124 D1 DE3582124 D1 DE 3582124D1 DE 8585308583 T DE8585308583 T DE 8585308583T DE 3582124 T DE3582124 T DE 3582124T DE 3582124 D1 DE3582124 D1 DE 3582124D1
Authority
DE
Germany
Prior art keywords
calcitonine
absorbable
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585308583T
Other languages
English (en)
Inventor
Seiya Kagatani
Shunji Hasumi
Takashi Sonobe
Masayoshi Aruga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP24889884 priority Critical
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3582124D1 publication Critical patent/DE3582124D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/808Calcitonin or derivatives
DE8585308583T 1984-11-26 1985-11-26 Absorbierbares calcitoninarzneimittel. Expired - Fee Related DE3582124D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP24889884 1984-11-26

Publications (1)

Publication Number Publication Date
DE3582124D1 true DE3582124D1 (de) 1991-04-18

Family

ID=17185073

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585308583T Expired - Fee Related DE3582124D1 (de) 1984-11-26 1985-11-26 Absorbierbares calcitoninarzneimittel.

Country Status (4)

Country Link
US (2) US4690952A (de)
EP (2) EP0371010A1 (de)
JP (1) JPS61267528A (de)
DE (1) DE3582124D1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546407B1 (fr) * 1983-05-24 1986-04-18 Therapeutique Applic Sa Medicament a activite anti-allergique pour administration locale a base d'acide n-acetyl(a,b)-aspartyl glutamique
HU198626B (en) * 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
IL84861A (en) * 1986-12-23 1992-09-06 Ciba Geigy Ag Nasal pharmaceutical composition comprising human calcitonin and viscosity-increasing swelling agent
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
US4804541A (en) * 1987-08-11 1989-02-14 Moleculon, Inc. Transdermal administration using benzyl alcohol
IT1223132B (it) * 1987-11-13 1990-09-12 Isf Spa Composizione farmaceutica per somministrazione nasale
GB2212062B (en) * 1987-11-13 1991-07-17 Isf Spa Pharmaceutical compositions containing a calcitonin and a glycyrrhizinate ab- sorption enhancer
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
USRE36744E (en) * 1988-09-16 2000-06-20 Ribogene, Inc. Nasal administration of benzodiazepine hypnotics
US4950664A (en) 1988-09-16 1990-08-21 Rugby-Darby Group Companies, Inc. Nasal administration of benzodiazepine hypnotics
JPH02104531A (en) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd Physiologically active peptide composition for nasal application
JPH0524137B2 (de) * 1988-12-23 1993-04-06 Asahi Chemical Ind
AT391269B (de) * 1988-12-30 1990-09-10 Burghart Kurt Pharmazeutische zubereitung
EP0460064A4 (en) * 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
IT8920486D0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
AT164080T (de) * 1990-05-10 1998-04-15 Bechgaard Int Res Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
JPH078806B2 (ja) * 1990-08-16 1995-02-01 久光製薬株式会社 カルシトニン類含有経鼻投与用乳剤
GB9108634D0 (en) * 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
IT1251685B (it) * 1991-10-11 1995-05-19 Isf Spa Composizioni farmaceutiche contenenti una calcitonina
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
WO1995011042A1 (fr) * 1993-10-21 1995-04-27 Hisamitsu Pharmaceutical Co., Inc. Composition administree par voie nasale et preparation contenant celle-ci
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
PL321094A1 (en) * 1994-12-22 1997-11-24 Astra Ab Parathyroid hormone (pth) containing preparation administered by inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
IL116460A (en) 1994-12-22 2003-10-31 Astra Ab Aerosol drug formulations for inhalation and method for their preparation
DE19503190A1 (de) * 1995-02-01 1996-08-08 Dietl Hans Mittel zur Beeinflussung von Störungen der Knochenbildung
EP0726075A1 (de) * 1995-02-08 1996-08-14 Therapicon Srl Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
WO1998046269A1 (fr) 1997-04-14 1998-10-22 Tt Pharmaceuticals, Inc. Preparation absorbable par les muqueuses
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
IT1294191B1 (it) * 1997-09-05 1999-03-22 Alfa Wassermann Spa Composizioni farmaceutiche contenenti calcitonina in un dosatore spray per somministrazione intranasale.
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
CA2399505C (en) 2000-02-04 2012-01-03 Unigene Laboratories, Inc. Nasal calcitonin formulations
CA2403690A1 (en) * 2000-03-14 2001-09-21 National Jewish Medical And Research Center Method for reducing allergen-induced airway hyperresponsiveness
GB2368792A (en) * 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US20030017181A1 (en) 2001-05-31 2003-01-23 Rood Gloria A. Dermatological compositions and methods
AU2003276686B2 (en) * 2002-08-28 2009-03-26 Lupin Ltd. Herbal extract comprising a mixture of saponins obtained from Sapindus trifoliatus for anticonvulsant activity
JP4543274B2 (ja) * 2002-10-01 2010-09-15 大正製薬株式会社 点鼻剤組成物
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
GB0308732D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
GB2417202A (en) * 2004-08-16 2006-02-22 Cipla Ltd Pharmaceutical preparation comprising calcitonin
DK2720699T3 (en) * 2011-06-14 2018-08-20 Hale Biopharma Ventures Llc Administration of benzodiazepine
EP2775831A4 (de) 2011-10-21 2015-08-12 Seachaid Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verwendungen davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151276A (en) * 1975-05-12 1979-04-24 Armour Pharmaceutical Company Method of suppressing gastric acid secretion by the oral administration of calcitonin
CA1098444A (en) * 1975-05-26 1981-03-31 Leo Geller Peptide preparations with prolonged action
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
EP0037943B1 (de) * 1980-03-31 1985-08-14 Teijin Limited Pharmazeutische Zusammensetzung zur rektalen Verabreichung und daraus hergestellte Zäpfchen
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
IL70489D0 (en) * 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
JPS6237016B2 (de) * 1983-03-09 1987-08-10 Teijin Ltd
CH657858A5 (de) * 1983-06-27 1986-09-30 Ciba Geigy Ag Substanz aus der gruppe der calcitonine.
GB8407907D0 (en) * 1984-03-27 1984-05-02 Macintyre I Organic compounds

Also Published As

Publication number Publication date
EP0371010A1 (de) 1990-05-30
EP0183527A3 (en) 1987-09-23
JPS61267528A (en) 1986-11-27
US4788221A (en) 1988-11-29
EP0183527A2 (de) 1986-06-04
US4690952A (en) 1987-09-01
EP0183527B1 (de) 1991-03-13

Similar Documents

Publication Publication Date Title
DE3586794T2 (de) Arzneimittel mit psychotroper wirkung.
DE3877193D1 (de) Wegwerfwindel.
DE3583455D1 (de) Salbenbase.
DE3587168D1 (de) Glucoamylasegen.
DE3586545D1 (de) Erhoehte schmerzlosigkeit bewirkende pharmazeutische zusammensetzungen.
DE3852793D1 (de) Polyethylenglykolcarbaminate.
DE69003042D1 (de) Katheter.
DE58903924D1 (de) Rollenbahn.
DE68907659D1 (de) Warmhaertende organosiloxanzusammensetzung.
DE69002926T2 (de) Abgabevorrichtung.
DE3687987T2 (de) Verpackung.
DE3672091D1 (de) Enossales implantat.
DE3650108D1 (de) Saugfähiger Artikel.
DE3876469T2 (de) Hautaequivalent.
DE3789149D1 (de) Fördereinrichtung.
DE3876540T2 (de) Befestigungsmittel.
DE68906637D1 (de) Wafertraeger.
DE68921901T2 (de) Matrizen-dirigierte Photoligation.
DE68917895T2 (de) Katheter.
DE3889791D1 (de) Zerstäuber.
DE3675564D1 (de) Dosierungsverpackung.
DE3863846D1 (de) Absorbierender artikel.
DE3580041D1 (de) Behaelter.
DE3884461D1 (de) Antibiotikum-polymer zusammensetzung.
DE3484779D1 (de) Pharmazeutische mittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee